Next Article in Journal
Propensity Score Matching Analysis of Differential Outcomes in Holmium Laser Enucleation of the Prostate vs. Robotic-Assisted Simple Prostatectomy
Previous Article in Journal
Two Cases of Symptomatic Tailgut Cysts
Previous Article in Special Issue
Investigating Menstruation and Adverse Pregnancy Outcomes: Oxymoron or New Frontier? A Narrative Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 17
10.3390/jcm13175137
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association between Subclinical Hypothyroidism and Adverse Pregnancy Outcomes in Assisted Reproduction Technology Singleton Pregnancies: A Retrospective Study

by
Yuichiro Narita
,
Hiroyuki Tsuda
*,
Eri Tsugeno
,
Yumi Nakamura
,
Miho Suzuki
,
Yumiko Ito
,
Atsuko Tezuka
and
Tomoko Ando
Department of Obstetrics and Gynecology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya 453-8511, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(17), 5137; https://doi.org/10.3390/jcm13175137
Submission received: 26 July 2024 / Revised: 22 August 2024 / Accepted: 27 August 2024 / Published: 29 August 2024
(This article belongs to the Special Issue Clinical Risks and Perinatal Outcomes in Pregnancy and Childbirth)
Browse Figure
Versions Notes

Abstract

:
Background/Objectives: Women with subclinical hypothyroidism (SCH) were reported to be at an increased perinatal risk. We aimed to investigate the relationship between SCH and perinatal outcomes in singleton pregnancies resulting from assisted reproduction technology (ART). Methods: We retrospectively examined the perinatal outcomes of ART singleton pregnancies in women who underwent thyroid function screening before conception and delivered at our hospital from January 2020 to July 2023. We defined SCH as thyroid-stimulating hormone (TSH) levels > 2.5 mU/L and normal free T4 levels. The patients were categorized into three groups: normal thyroid function (group A), SCH without levothyroxine therapy (group B), and SCH with levothyroxine therapy (group C). The risks of preterm birth, preeclampsia, fetal growth restriction, manual placental removal, and blood loss at delivery were compared among the three groups. Results: Out of the 650 ART singleton deliveries, 581 were assigned to group A, 34 to group B, and 35 to group C. The preterm birth rate at <34 weeks was significantly higher in group B and significantly lower in group C than in group A. The rate of preterm delivery at <34 weeks increased in correlation with TSH levels. Levothyroxine therapy was the significant preventive factor for preterm birth at <34 weeks. Conclusions: The preterm birth rate before 34 weeks was significantly higher in the SCH group. Levothyroxine therapy is a significant protective factor against preterm birth before 34 weeks. Universal screening for thyroid function and appropriate hormone therapy in pregnant women may help reduce perinatal risks, including preterm birth.

1. Introduction

Thyroid function studies using the Japanese adult general health examination system documented thyroid dysfunction in approximately 10% of cases, with subclinical hypothyroidism (SCH) accounting for half of the cases [1]. This finding suggests that many pregnant women may have undiagnosed SCH. SCH is defined as normal free T4 levels and elevated serum thyroid-stimulating hormone (TSH) levels. It is observed in 2.0–2.5% of screened pregnant women, according to reports from iodine-sufficient areas of the United States [2,3].
Some [4,5,6,7], but not all [8,9], studies have demonstrated that women with SCH have a higher perinatal risk of severe preeclampsia, preterm delivery, placental abruption, neonatal respiratory distress syndrome, and/or pregnancy loss than do euthyroid women. One meta-analysis from 19 cohort studies reported an odds ratio (OR) of 1.29 (95% confidence interval [CI], 1.01–1.64) for preterm birth [10], and another meta-analysis reported an OR of 1.53 (95% CI, 1.09–2.15) for preeclampsia [6]. Interestingly, preterm delivery rates increase with TSH levels as follows: 5.4% of pregnancies with TSH levels between 4 and 6 mU/L, 7.8% between 6 and 10 mU/L, and 11.4% with >10 mU/L [11]. Furthermore, limited data suggest that perinatal outcomes are worse in women undergoing in vitro fertilization (IVF) if their preconception TSH levels are >2.5 mU/L. In one study of pregnancies after IVF, 150 deliveries with a preconception TSH level < 2.5 mU/L resulted in higher gestational age and birth weight than 45 deliveries with a TSH level > 2.5 mU/L [12].
Because overt or SCH is thought to be associated with pregnancy complications and thyroid testing is common and easy to perform, attention has been focused on the utility of screening for thyroid dysfunction in all pregnant women. To our knowledge, no high-quality studies have used a universal screening for thyroid function in pregnant women. The advantages and disadvantages of screening thyroid function in all pregnant women in early pregnancy remain inconclusive. This is because there are insufficient data to show not only the effects of thyroid disease on pregnancy but also the benefits of hormone therapy [13,14]. In Japan, universal screening for thyroid dysfunction in asymptomatic pregnant women is rare; however, universal screening for thyroid dysfunction is common in women initiating fertility treatment. This study aimed to examine the association between the presence of SCH and perinatal outcomes in assisted reproduction technology (ART) pregnancies using preconception thyroid function screening and the effects of thyroid hormone replacement (levothyroxine sodium hydrate) during pregnancy.

2. Materials and Methods

2.1. Participants

In this retrospective cohort study, we analyzed the perinatal outcomes of pregnancies delivered at the Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan, between January 2020 and July 2023. This study included ART singleton pregnancies in which thyroid function screening was performed before conception (n = 687). Among them, we excluded 22 cases of overt thyroid disease (n = 22) and 15 cases of placenta previa (n = 15) (Figure 1).
This study was approved by the Ethics Committee of our hospital (approval number: 2023-070).

2.2. Data Collection and Definition

In this study, we defined SCH as preconception TSH levels > 2.5 mU/L and normal free T4 levels. Patients with preconception TSH levels < 2.5 mU/L were assigned to group A (normal group). Patients with SCH were categorized into two groups: women who took levothyroxine sodium hydrate before and throughout pregnancy (group C) and those who did not (group B). In group C, after diagnosing SCH, patients were treated by an endocrinologist with levothyroxine sodium hydrate (approximately 0.5 µg/kg/day) and followed up regularly (every 2–4 weeks) for TSH and free T4 levels. Doses were increased (12–25 µg/day) until the TSH level fell below 2.5 mU/L. Once the target level was achieved, the maintenance dose was continued until the end of pregnancy (TSH and free T4 levels were monitored every 4–6 weeks). Moreover, all patients in group C had normalized TSH levels at the time of pregnancy. The following maternal and perinatal data were obtained from medical records: age, parity, body mass index before pregnancy, history of abortion, history of previous cesarean deliveries, gestational weeks at delivery, preterm birth (at <37 weeks, <34 weeks, <32 weeks, and <28 weeks), preeclampsia, fetal growth restriction (FGR), blood loss at delivery, transfusion, manual placental removal, and the value of TSH before pregnancy. We also obtained the birth weight of the newborns. Preeclampsia was defined as the appearance of gestational hypertension, proteinuria, and/or signs of end-organ impairment during pregnancy [15]. FGR was defined as neonatal body weight at birth <−1.5 than the standard deviation for gestational age in Japan [16].

2.3. Statistical Analyses

All statistical analyses were performed using EZR (v. 1.37, Saitama, Japan). The Shapiro–Wilk test was used to analyze the normality of the data. Continuous variables among the three groups were compared using the Kruskal–Wallis test. The Mann–Whitney U test was used for nonparametric comparisons during the post hoc analysis. Nominal data were analyzed using Fisher’s exact test. In multivariate analysis, maternal age, body mass index, parity, preeclampsia, FGR, history of abortion, levothyroxine therapy, and TSH levels were selected as variables associated with preterm birth. p < 0.05 was considered statistically significant.

3. Results

Among the 650 ART singleton deliveries in this study, 581 were assigned to group A, 34 to group B, and 35 to group C (Figure 1). The three groups did not significantly differ in terms of age, body mass index, history of previous cesarean deliveries, blood loss at delivery, manual placental removal, transfusion, preeclampsia, FGR, history of abortion, and neonatal body weight (Table 1).
Expectedly, the TSH levels were significantly lower in group A than in groups B and C (p < 0.001). After the initiation of levothyroxine therapy in group C, the TSH levels were 1.11 (±0.60) mU/L. The rate of preterm birth at <34 weeks was significantly higher in group B (14.7%) and significantly lower in group C (0%) than in group A (p = 0.046). Group C had no cases of preterm delivery under 34 weeks. The preterm birth rate at <37 weeks was lower in group C (5.7%) than in groups A and B; however, the difference was not significant (p = 0.059) (Table 1).
When 69 patients diagnosed with SCH (groups B and C) were examined for the rate of preterm delivery at <34 weeks per TSH level, the rates were 1/30 (3.3%) at TSH levels of 2.5–3 mU/L, 2/22 (9.1%) at 3–4 mU/L, and 2/17 (11.8%) at >4 mU/L. The rate of preterm delivery at <34 weeks increased according to the TSH levels, but the difference was not statistically significant.
The results of multivariate analysis of the risk of preterm birth at <37 weeks are shown in Table 2.
When performing the multivariate analysis, we included maternal age, body mass index, parity, preeclampsia, FGR, history of abortion, levothyroxine therapy, and TSH levels as variables to calculate the OR. Preeclampsia (OR = 4.98) and FGR (OR = 3.31) were significant risk factors for preterm birth at <37 weeks; however, levothyroxine therapy and TSH levels did not affect the risk of preterm birth at <37 weeks.
The results of the multivariate analysis of the risk of preterm birth at <34 weeks are shown in Table 3.
In the multivariate analysis, we included maternal age, body mass index, parity, preeclampsia, FGR, history of abortion, levothyroxine therapy, and TSH level as variables to calculate the OR. The significant risk factor for preterm birth at <34 weeks was preeclampsia (OR = 3.65; 95% CI, 1.65–8.09), and the significant preventive factor was levothyroxine therapy (OR = 0.117; 95% CI, 0.015–0.948).
Of the 69 patients with TSH levels > 2.5 mU/L in this study, thyroid peroxidase (TPO) antibodies were measured in 44 patients (63.8%). TPO antibodies were positive in 4 out of 19 patients (21.1%) in group B and 6 out of 25 patients (24%) in group C, with no significant difference between the two groups (p = 0.817).
The results of multivariate analysis assessing the impact of TSH on perinatal outcomes are shown in Table S1. TSH levels were not identified as an independent risk factor for various perinatal complications, including preterm birth, preeclampsia, FGR, cesarean delivery, and the need for transfusion.

4. Discussion

We investigated the effects of SCH and its preconception treatment on the perinatal outcomes of ART singleton pregnancies, all of which were screened for thyroid function prior to conception. The preterm birth rate at <34 weeks was significantly higher in patients with SCH; however, it was significantly lower in patients with SCH treated with levothyroxine therapy before pregnancy. The rate of preterm delivery at <34 weeks increased according to TSH levels. The multivariate analysis revealed that levothyroxine therapy was a significant protective factor against preterm birth at <34 weeks.
Women with SCH have a higher risk of preeclampsia and preterm delivery than euthyroid women [5,6,10]. However, in the present study, we found that the rate of preterm birth at <34 weeks was significantly higher in patients with SCH and was not significantly different for preterm birth (<37, <32, and <28 weeks) and preeclampsia. The results may be because our study was limited to cases of singleton ART pregnancies. In general, women undergoing infertility treatment appear to have a small but statistically significant increase in risk for preterm birth, low birth weight, and severe maternal morbidity (such as preeclampsia, antepartum hemorrhage, need for transfusion, thrombotic embolism, and disseminated intravascular coagulation) [17,18,19]. Therefore, the background factors of ART pregnancy may have influenced these results. Limited data also suggest that in women undergoing IVF, cases with preconception TSH levels > 2.5 mU/L may result in a lower gestational age at delivery and a lower birth weight [12]. However, other pregnancy outcomes, such as the rate of preterm birth, the rate of FGR, preeclampsia, blood loss during delivery, and the need for transfusion, may not have been examined. To our knowledge, there are no other studies on the association between SCH and adverse outcomes in ART pregnancies, and we believe that the present study provides new insights. In addition, the rate of preterm delivery at <34 weeks increased according to the TSH level but was not significant in the present study. The results are significantly interesting, but the limited number of cases did not allow for significant differences. Previous studies have reported that TSH levels correlate with preterm birth rates [11], but there are no high-quality data stratified by cutoff of the TSH level, presence of antithyroid antibodies, or treatment for SCH. Thus, future studies are required.
Screening for hypothyroidism in asymptomatic pregnant women during early pregnancy remains controversial. In prospective trials, even with universal screening for thyroid function, there was no improvement in pregnancy outcomes compared with a targeted or no screening group [20]. In a randomized trial, >4500 women in their first trimester of pregnancy participated. They were randomly assigned to either a universal screening group or a case-finding group [21]. Overall, the total number of adverse outcomes was similar between the case-finding and universal screening groups. However, secondary analysis revealed that low-risk women diagnosed with SCH and treated with thyroid hormone therapy in the universal screening group had 57% fewer adverse outcomes (preterm birth, preeclampsia, gestational diabetes, and miscarriage) than low-risk women diagnosed with SCH but not treated in the case-finding group [21]. In addition, it has been suggested that universal screening may show higher cost-effectiveness [22,23]. As mentioned above, universal screening of thyroid function in pregnant women has its advantages and disadvantages, but the results of our study suggest that, although limited to ART pregnancies, preconception screening and treatment for SCH may contribute to improved perinatal outcomes. In the future, universal screening for thyroid function and proper hormone therapy in pregnant women may contribute to reducing perinatal risks, including preterm birth.
There are no established criteria for the indications for SCH treatment in pregnant women. In a multicenter trial, 677 pregnant women with SCH (median TSH, 4.4 mU/L; free T4, normal) were randomized to levothyroxine therapy or placebo group [24]. Levothyroxine treatment had no significant effect on maternal or fetal outcomes, such as preterm delivery, preeclampsia, gestational hypertension, and miscarriage, and there was no interaction effect with TPO antibody positivity. In a meta-analysis of nine randomized controlled trials and 13 cohort studies, there was no benefit of SCH treatment on pregnancy outcomes [9]. However, evaluation of antithyroid antibodies is also important in women diagnosed with SCH [4]. In a systematic review by the American Thyroid Association (ATA) regarding pregnancy-specific complications, although there is clearly a higher risk in TPO-positive women with TSH > 2.5 mU/L, the risk was not constant in TPO-negative women, even at significantly higher TSH levels (>5–10 mU/L) [25]. In a trial of 131 TPO antibody-positive women diagnosed with SCH, levothyroxine replacement significantly reduced the rate of preterm delivery, especially in women with TSH ≥ 4 mU/L [26]. At present, it is uncertain whether thyroid hormone replacement therapy reduces perinatal risk in women with SCH. A recent meta-analysis suggested that high levels of TPO antibodies, even in euthyroid pregnant women, could adversely influence pregnancy outcomes after ART [27]. In contrast, no significant differences were observed in pregnancy outcomes following fresh or frozen embryo transfer in euthyroid patients with TPO and/or antithyroglobulin antibodies [28]. Therefore, the perinatal risk of antithyroid antibodies alone in euthyroid patients remains inconclusive. In the present study, we demonstrated that levothyroxine therapy could reduce the risk of preterm birth at <34 weeks among SCH patients with TSH ≥ 2.5 mU/L. However, complete data on anti-TPO antibodies were not available; therefore, further studies are required in the future.
Furthermore, in the present study, the diagnostic criterion for SCH was defined as TSH level > 2.5 mU/L for the following reasons. First, the study included ART pregnancies. Pregnancy outcomes for women undergoing IVF may be worse among those with preconception TSH levels > 2.5 mU/L [12]. Second, the treatment goal for SCH should be to achieve a TSH level of ≤2.5 mU/L. Finally, according to the ATA guidelines, levothyroxine therapy should be considered for TPO antibody-positive women with TSH levels > 2.5 mU/L. Moreover, we decided to use the cutoff of 2.5 mU/L because complete data on TPO antibodies were not available. Therefore, the interpretation of our findings is that levothyroxine therapy with TSH levels > 2.5 mU/L, regardless of the presence of autoantibodies, can reduce the risk of preterm birth at <34 weeks.
This study included cases of ART singleton pregnancies in which thyroid function screening was performed before fertility treatment. The SCH rate was higher in the infertile women than in the control women (healthy women with confirmed fertility) (13.9% vs. 3.9%) [29]. A recent study demonstrated that pregnant women with singleton ART with a history of abortion or spontaneous abortion were more likely to have thyroid-related diseases [30]. In Japan, universal screening of thyroid function is commonly performed before fertility treatment. In addition, all patients in group C were already receiving appropriate levothyroxine therapy by an endocrinologist at the time of conception and were appropriately managed for SCH throughout their pregnancy. The strength of this study is that the patients’ backgrounds were well-established. Second, because it is a single-center study, there is consistency in pregnancy management and treatment policies, and a certain quality of care is maintained. Our institution follows the Guidelines for Obstetrical Practice in Japan and provides standardized care. The limitations of this study include the following: inclusion of only singleton data from ART pregnancies; the absence of data on placental abruption, neonatal respiratory distress syndrome, and/or pregnancy loss among adverse pregnancy outcomes; the absence of data on the prognosis of the child, such as respiratory disorders and cognitive function; and the absence of data on anti-TPO antibodies. Another limitation is that the criteria for levothyroxine therapy (groups B and C) in patients with SCH are unknown. Finally, the number of cases examined in this study was limited, especially in the SCH groups (34 and 35 cases in groups B and C, respectively); therefore, it is possible that statistical differences could not be detected. This study has the following inherent limitations: limitations inherent to the study design, the potential for selection bias, and the inability to generalize the findings to different populations. Therefore, large-scale studies are required in the future.
In conclusion, the rate of preterm birth at <34 weeks is significantly higher in patients with SCH; however, it is significantly lower in patients with SCH treated with levothyroxine therapy before and during pregnancy. Moreover, levothyroxine therapy is a significant protective factor against preterm birth at <34 weeks. These data provide valuable information for future clinical practice. Universal screening of thyroid function and proper hormone therapy in all pregnant women may reduce perinatal risks, including preterm birth. Further large-scale studies are warranted to estimate the perinatal risk of SCH, including data on antithyroid antibodies and the effects of levothyroxine therapy on perinatal risk, and to set cutoff values for appropriate therapeutic interventions.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm13175137/s1, Table S1: Multivariate logistic regression analysis assessing the impact of TSH on perinatal outcomes.

Author Contributions

All authors contributed to the conception and design of this study. Material preparation, data collection, and analysis, Y.N. (Yuichiro Narita), E.T., Y.N. (Yumi Nakamura), M.S., Y.I., A.T., and T.A.; writing of the first draft of the manuscript, H.T.; and all authors commented on the previous versions of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Japanese Red Cross, Aichi Medical Center, Nagoya Daiichi Hospital (Research Grant NFRCH 24-0008). The funding body had no role in the study design, data collection, analysis, interpretation, or the writing of the manuscript.

Institutional Review Board Statement

This study was conducted in accordance with the principles outlined in the 1964 Declaration of Helsinki. This study was approved by the Ethics Committee of the Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan (approval number: 2023-070 date of approval: 2 June 2023). Data were compiled and analyzed so that personal information could not be identified.

Informed Consent Statement

Patient informed consent was waived as this study used anonymous clinical data.

Data Availability Statement

The data in the manuscript will not be deposited. However, upon request, we will submit data (deidentified participant data) that support the findings of this study.

Acknowledgments

We thank Atsushi Kubo for collecting data from the medical records.

Conflicts of Interest

The authors declare no conflicts of interest. The authors alone are responsible for the content and writing of this manuscript.

References

  1. Kasagi, K.; Takahashi, N.; Inoue, G.; Honda, T.; Kawachi, Y.; Izumi, Y. Thyroid function in Japanese adults as assessed by a general health checkup system in relation with thyroid-related antibodies and other clinical parameters. Thyroid 2009, 19, 937–944. [Google Scholar] [CrossRef]
  2. Allan, W.C.; Haddow, J.E.; Palomaki, G.E.; Williams, J.R.; Mitchell, M.L.; Hermos, R.J.; Faix, J.D.; Klein, R.Z. Maternal thyroid deficiency and pregnancy complications: Implications for population screening. J. Med. Screen. 2000, 7, 127–130. [Google Scholar] [CrossRef] [PubMed]
  3. Klein, R.Z.; Haddow, J.E.; Faix, J.D.; Brown, R.S.; Hermos, R.J.; Pulkkinen, A.; Mitchell, M.L. Prevalence of thyroid deficiency in pregnant women. Clin. Endocrinol. 1991, 35, 41–46. [Google Scholar] [CrossRef]
  4. Liu, H.; Shan, Z.; Li, C.; Mao, J.; Xie, X.; Wang, W.; Fan, C.; Wang, H.; Zhang, H.; Han, C.; et al. Maternal subclinical hypothyroidism, thyroid autoimmunity, and the risk of miscarriage: A prospective cohort study. Thyroid 2014, 24, 1642–1649. [Google Scholar] [CrossRef] [PubMed]
  5. Lee, S.Y.; Cabral, H.J.; Aschengrau, A.; Pearce, E.N. Associations between maternal thyroid function in pregnancy and obstetric and perinatal outcomes. J. Clin. Endocrinol. Metab. 2020, 105, e2015–e2023. [Google Scholar] [CrossRef]
  6. Toloza, F.J.K.; Derakhshan, A.; Männistö, T.; Bliddal, S.; Popova, P.V.; Carty, D.M.; Chen, L.; Taylor, P.; Mosso, L.; Oken, E.; et al. Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: A systematic review and individual-participant data meta-analysis. Lancet Diabetes Endocrinol. 2022, 10, 243–252. [Google Scholar] [CrossRef] [PubMed]
  7. Breathnach, F.M.; Donnelly, J.; Cooley, S.M.; Geary, M.; Malone, F.D. Subclinical hypothyroidism as a risk factor for placental abruption: Evidence from a low-risk primigravid population. Aust. N. Z. J. Obstet. Gynaecol. 2013, 53, 553–560. [Google Scholar] [CrossRef]
  8. Cleary-Goldman, J.; Malone, F.D.; Lambert-Messerlian, G.; Sullivan, L.; Canick, J.; Porter, T.F.; Luthy, D.; Gross, S.; Bianchi, D.W.; D’Alton, M.E. Maternal thyroid hypofunction and pregnancy outcome. Obstet. Gynecol. 2008, 112, 85–92. [Google Scholar] [CrossRef]
  9. Jiao, X.F.; Zhang, M.; Chen, J.; Wei, Q.; Zeng, L.; Liu, D.; Zhang, C.; Li, H.; Zou, K.; Zhang, L.; et al. The impact of levothyroxine therapy on the pregnancy, neonatal and childhood outcomes of subclinical hypothyroidism during pregnancy: An updated systematic review, meta-analysis and trial sequential analysis. Front. Endocrinol. 2022, 13, 964084. [Google Scholar] [CrossRef] [PubMed]
  10. Consortium on Thyroid and Pregnancy—Study Group on Preterm Birth—Study Group on Preterm Birth; Korevaar, T.I.M.; Derakhshan, A.; Taylor, P.N.; Meima, M.; Chen, L.; Bliddal, S.; Carty, D.M.; Meems, M.; Vaidya, B.; et al. Association of thyroid function test abnormalities and thyroid autoimmunity with preterm birth: A systematic review and meta-analysis. JAMA 2019, 322, 632–641. [Google Scholar] [CrossRef] [PubMed]
  11. Knøsgaard, L.; Andersen, S.; Hansen, A.B.; Vestergaard, P.; Andersen, S.L. Maternal hypothyroidism and adverse outcomes of pregnancy. Clin. Endocrinol. 2023, 98, 719–729. [Google Scholar] [CrossRef]
  12. Baker, V.L.; Rone, H.M.; Pasta, D.J.; Nelson, H.P.; Gvakharia, M.; Adamson, G.D. Correlation of thyroid stimulating hormone (TSH) level with pregnancy outcome in women undergoing in vitro fertilization. Am. J. Obstet. Gynecol. 2006, 194, 1668–1674, discussion 1674. [Google Scholar] [CrossRef] [PubMed]
  13. Blatt, A.J.; Nakamoto, J.M.; Kaufman, H.W. National status of testing for hypothyroidism during pregnancy and postpartum. J. Clin. Endocrinol. Metab. 2012, 97, 777–784. [Google Scholar] [CrossRef]
  14. Vaidya, B.; Hubalewska-Dydejczyk, A.; Laurberg, P.; Negro, R.; Vermiglio, F.; Poppe, K. Treatment and screening of hypothyroidism in pregnancy: Results of a European survey. Eur. J. Endocrinol. 2012, 166, 49–54. [Google Scholar] [CrossRef]
  15. Watanabe, K.; Matsubara, K.; Nakamoto, O.; Ushijima, J.; Ohkuchi, A.; Koide, K.; Makino, S.; Mimura, K.; Morikawa, M.; Naruse, K.; et al. Outline of the new definition and classification of “hypertensive disorders of pregnancy (HDP)”; a revised JSSHP statement of 2005. Hypertens. Res. Pregnancy 2018, 6, 33–37. [Google Scholar] [CrossRef]
  16. Yoshida, S.; Unno, N.; Kagawa, H.; Shinozuka, N.; Kozuma, S.; Taketani, Y. Prenatal detection of a high-risk group for intrauterine growth restriction based on sonographic fetal biometry. Int. J. Gynaecol. Obstet. 2000, 68, 225–232. [Google Scholar] [CrossRef]
  17. Jaques, A.M.; Amor, D.J.; Baker, H.W.G.; Healy, D.L.; Ukoumunne, O.C.; Breheny, S.; Garrett, C.; Halliday, J.L. Adverse obstetric and perinatal outcomes in subfertile women conceiving without assisted reproductive technologies. Fertil. Steril. 2010, 94, 2674–2679. [Google Scholar] [CrossRef] [PubMed]
  18. Declercq, E.; Luke, B.; Belanoff, C.; Cabral, H.; Diop, H.; Gopal, D.; Hoang, L.; Kotelchuck, M.; Stern, J.E.; Hornstein, M.D. Perinatal outcomes associated with assisted reproductive technology: The Massachusetts Outcomes Study of Assisted Reproductive Technologies (MOSART). Fertil. Steril. 2015, 103, 888–895. [Google Scholar] [CrossRef]
  19. Murugappan, G.; Li, S.; Lathi, R.B.; Baker, V.L.; Luke, B.; Eisenberg, M.L. Increased risk of severe maternal morbidity among infertile women: Analysis of US claims data. Am. J. Obstet. Gynecol. 2020, 223, 404.e1–404.e20. [Google Scholar] [CrossRef]
  20. Lazarus, J.H.; Bestwick, J.P.; Channon, S.; Paradice, R.; Maina, A.; Rees, R.; Chiusano, E.; John, R.; Guaraldo, V.; George, L.M.; et al. Antenatal thyroid screening and childhood cognitive function. N. Engl. J. Med. 2012, 366, 493–501. [Google Scholar] [CrossRef]
  21. Negro, R.; Schwartz, A.; Gismondi, R.; Tinelli, A.; Mangieri, T.; Stagnaro-Green, A. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J. Clin. Endocrinol. Metab. 2010, 95, 1699–1707. [Google Scholar] [CrossRef] [PubMed]
  22. Thung, S.F.; Funai, E.F.; Grobman, W.A. The cost-effectiveness of universal screening in pregnancy for subclinical hypothyroidism. Am. J. Obstet. Gynecol. 2009, 200, 267.e1–267.e7. [Google Scholar] [CrossRef] [PubMed]
  23. Dosiou, C.; Barnes, J.; Schwartz, A.; Negro, R.; Crapo, L.; Stagnaro-Green, A. Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. J. Clin. Endocrinol. Metab. 2012, 97, 1536–1546. [Google Scholar] [CrossRef] [PubMed]
  24. Casey, B.M.; Thom, E.A.; Peaceman, A.M.; Varner, M.W.; Sorokin, Y.; Hirtz, D.G.; Reddy, U.M.; Wapner, R.J.; Thorp, J.M., Jr.; Saade, G.; et al. Treatment of subclinical hypothyroidism or hypothyroxinemia in pregnancy. N. Engl. J. Med. 2017, 376, 815–825. [Google Scholar] [CrossRef]
  25. Alexander, E.K.; Pearce, E.N.; Brent, G.A.; Brown, R.S.; Chen, H.; Dosiou, C.; Grobman, W.A.; Laurberg, P.; Lazarus, J.H.; Mandel, S.J.; et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017, 27, 315–389. [Google Scholar] [CrossRef] [PubMed]
  26. Nazarpour, S.; Ramezani Tehrani, F.; Simbar, M.; Tohidi, M.; Alavi Majd, H.; Azizi, F. Effects of levothyroxine treatment on pregnancy outcomes in pregnant women with autoimmune thyroid disease. Eur. J. Endocrinol. 2017, 176, 253–265. [Google Scholar] [CrossRef]
  27. Zhang, S.; Yang, M.; Li, T.; Yang, M.; Wang, W.; Chen, Y.; Ding, Y.; Liu, J.; Xu, X.; Zhang, J.; et al. High level of thyroid peroxidase antibodies as a detrimental risk of pregnancy outcomes in euthyroid women undergoing ART: A meta-analysis. Mol. Reprod. Dev. 2023, 90, 218–226. [Google Scholar] [CrossRef]
  28. Yang, X.; Qiu, S.; Jiang, W.; Huang, Z.; Shi, H.; Du, S.; Sun, Y.; Zheng, B. Impact of thyroid autoimmunity on pregnancy outcomes in euthyroid women following fresh/frozen–thawed embryo transfer. Clin. Endocrinol. 2023, 99, 113–121. [Google Scholar] [CrossRef] [PubMed]
  29. Abalovich, M.; Mitelberg, L.; Allami, C.; Gutierrez, S.; Alcaraz, G.; Otero, P.; Levalle, O. Subclinical hypothyroidism and thyroid autoimmunity in women with infertility. Gynecol. Endocrinol. 2007, 23, 279–283. [Google Scholar] [CrossRef]
  30. Sun, H.; Su, X.; Liu, Y.; Li, G.; Liu, X.; Du, Q. Association between abortion history and perinatal and neonatal outcomes of singleton pregnancies after assisted reproductive technology. J. Clin. Med. 2022, 12, 1. [Google Scholar] [CrossRef]
Jcm 13 05137 g001
Figure 1. Study flowchart of patient enrollment.
Figure 1. Study flowchart of patient enrollment.
Jcm 13 05137 g001
Table 1. Maternal characteristics and perinatal outcomes of this study.
Table 1. Maternal characteristics and perinatal outcomes of this study.
Group A
(n = 581)		Group B
(n = 34)		Group C
(n = 35)		p-Value
Maternal age (years) *36.5 (±4.3)36.6 (±4.7)36.5 (±3.8)0.988
Pre-pregnant BMI (kg/m2) *21.5 (±3.4)22.0 (±2.6)21.8 (±2.8)0.634
History of abortion218/581 (37.5%)11/34 (32.4%)8/35 (22.9%)0.194
Preterm birth at <37 weeks106/581 (18.2%)9/34 (26.5%)2/35 (5.7%)0.059
Preterm birth at <34 weeks36/581 (6.2%)5/34 (14.7%)0/35 (0%)0.046
Preterm birth at <32 weeks32/581 (5.5%)1/34 (2.9%)0/35 (0%)0.411
Preterm birth at <28 weeks16/581 (2.8%)0/34 (0%)0/35 (0%)1
Preeclampsia56/581 (9.6%)3/34 (8.8%)4/35 (11.4%)0.945
Fetal growth restriction23/581 (4.0%)1/34 (2.9%)0/35 (0%)0.768
Cesarean delivery272/581 (46.8%)15/34 (44.1%)19/34 (54.3%)0.641
Blood loss at delivery (mL) *812 (±676)970 (±716)788 (±406)0.393
Manual placental removal53/581 (9.1%)3/34 (8.8%)5/35 (14.3%)0.591
Transfusion33/581 (5.7%)1/34 (2.9%)0/35 (0%)0.374
Neonatal birth weight (g) *2901 (±1339)2819 (±640)3064 (±475)0.705
TSH value (mU/L) *1.36 (±0.57)4.02 (±2.47)3.55 (±1.07)<0.001
BMI, body mass index; TSH, thyroid-stimulating hormone. * Median (range).
Table 2. Multivariate logistic regression analysis for preterm birth at <37 weeks.
Table 2. Multivariate logistic regression analysis for preterm birth at <37 weeks.
Adjusted OR95% CIp-Value
Maternal age1.000.956–1.050.880
Pre-pregnant BMI1.000.939–1.070.991
Nulliparous0.950.602–1.500.822
History of abortion0.970.621–1.520.899
Preeclampsia4.982.81–8.81<0.001
Fetal growth restriction3.311.31–8.340.011
Levothyroxine therapy1.360.378–1.360.230
TSH value1.050.485–2.290.895
BMI, body mass index; TSH, thyroid-stimulating hormone; OR, odds ratio; CI, confidence interval.
Table 3. Multivariate logistic regression analysis for preterm birth at <34 weeks.
Table 3. Multivariate logistic regression analysis for preterm birth at <34 weeks.
Adjusted OR 95% CIp-Value
Maternal age1.000.926–1.070.915
Pre-pregnant BMI1.030.942–1.130.506
Nulliparous1.200.567–2.530.638
History of abortion1.200.606–2.400.595
Preeclampsia3.651.65–8.090.001
Fetal growth restriction2.920.877–9.740.081
Levothyroxine therapy0.1170.015–0.9480.044
TSH value2.180.750–6.360.152
BMI, body mass index; TSH, thyroid-stimulating hormone; OR, odds ratio; CI, confidence interval.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Narita, Y.; Tsuda, H.; Tsugeno, E.; Nakamura, Y.; Suzuki, M.; Ito, Y.; Tezuka, A.; Ando, T. Association between Subclinical Hypothyroidism and Adverse Pregnancy Outcomes in Assisted Reproduction Technology Singleton Pregnancies: A Retrospective Study. J. Clin. Med. 2024, 13, 5137. https://doi.org/10.3390/jcm13175137

AMA Style

Narita Y, Tsuda H, Tsugeno E, Nakamura Y, Suzuki M, Ito Y, Tezuka A, Ando T. Association between Subclinical Hypothyroidism and Adverse Pregnancy Outcomes in Assisted Reproduction Technology Singleton Pregnancies: A Retrospective Study. Journal of Clinical Medicine. 2024; 13(17):5137. https://doi.org/10.3390/jcm13175137

Chicago/Turabian Style

Narita, Yuichiro, Hiroyuki Tsuda, Eri Tsugeno, Yumi Nakamura, Miho Suzuki, Yumiko Ito, Atsuko Tezuka, and Tomoko Ando. 2024. "Association between Subclinical Hypothyroidism and Adverse Pregnancy Outcomes in Assisted Reproduction Technology Singleton Pregnancies: A Retrospective Study" Journal of Clinical Medicine 13, no. 17: 5137. https://doi.org/10.3390/jcm13175137

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop